Oncogenic MYC is dysregulated or aberrantly expressed in approximately 70% of human cancers, including breast, bone, brain, B-cell lymphoma, colon, cervix, lung, pancreatic, and prostate tumors [8,9,10,11,12], with correlating poor prognosis and aggressive disease [13,14]. Here, MYC is linked to cancer.